Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Gains from Investment Securities (2019 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed Gains from Investment Securities for 3 consecutive years, with -$10000.0 as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Gains from Investment Securities rose 99.88% year-over-year to -$10000.0, compared with a TTM value of $5000.0 through Dec 2021, changed N/A, and an annual FY2024 reading of $249000.0, changed N/A over the prior year.
  • Gains from Investment Securities was -$10000.0 for Q4 2021 at Black Diamond Therapeutics, down from $15000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $8.3 million in Q3 2020 and bottomed at -$8.3 million in Q4 2020.
  • Average Gains from Investment Securities over 3 years is -$2750.0, with a median of $2500.0 recorded in 2019.
  • Peak annual rise in Gains from Investment Securities hit 82640.0% in 2020, while the deepest fall reached 13033.33% in 2020.
  • Year by year, Gains from Investment Securities stood at -$63000.0 in 2019, then crashed by 13033.33% to -$8.3 million in 2020, then soared by 99.88% to -$10000.0 in 2021.
  • Business Quant data shows Gains from Investment Securities for BDTX at -$10000.0 in Q4 2021, $15000.0 in Q3 2021, and $6000.0 in Q2 2021.